1.
Blauvelt A, Gottlieb A, Fierens F, Brock F, Wiegratz S, Sofen H. Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT. J of Skin [Internet]. 2020Oct.27 [cited 2021Jan.24];4(6):s85. Available from: https://jofskin.org/index.php/skin/article/view/1118